Enzymatic Synthesis of Glycosaminoglycan Heparin

Robert J. Linhardt, Ph.D.,¹ Jonathan S. Dordick, Ph.D.,² Paul L. Deangelis, Ph.D.,² and Jian Liu, Ph.D.¹

ABSTRACT

Heparin and its low molecular weight heparin derivatives, widely used as clinical anticoagulants, are acidic polysaccharide members of a family of biomacromolecules called glycosaminoglycans (GAGs). Heparin and the related heparan sulfate are biosynthesized in the Golgi apparatus of eukaryotic cells. Heparin is a polycomponent drug that can be prepared for clinical use by extraction from animal tissues. A heparin pentasaccharide, fondaparinux, has also been prepared through chemical synthesis for use as a homogenous anticoagulant drug. Recent enabling technologies suggest that it may now be possible to synthesize heparin and its derivatives enzymatically. Moreover, new technologies including advances in synthetic carbohydrate synthesis, enzyme-based GAG synthesis, micro- and nano-display of GAGs, rapid on-line structural analysis, and microarray/microfluidic technologies might be applied to the enzymatic synthesis of heparins with defined structures and exhibiting selected activities. The advent of these new technologies also makes it possible to consider the construction of an artificial Golgi to increase our understanding of the cellular control of GAG biosynthesis in this organelle.

KEYWORDS: Heparin, enzymes, biosynthesis, Golgi, microfluidics

Heparin, a widely used anticoagulant, was introduced clinically soon after its discovery in 1916.¹ For the next 70 years, it was the agent of choice for clinical anticoagulation. Heparin is an acidic polysaccharide isolated by extraction from animal tissues including porcine intestine.² The heparin pentasaccharide is a member of the glycosaminoglycan (GAG) family and comprises a repeating disaccharide structure of 1→4-linked hexuronic acid and glucosamine saccharide residues (Fig. 1). It is highly sulfated and has an average molecular weight of 10 to 15 kDa.³ Although heparin exerts its anticoagulant effect in several ways, its most well-understood activity involves binding to the serine protease inhibitor antithrombin III (AT), which undergoes a conformational change, making it a potent inhibitor of thrombin and other serine proteases (i.e., factor [F] Xa) important in the blood coagulation cascade.⁴

During the last 30 years, low molecular weight heparins (LMWHs) have been under extensive development as improved anticoagulant agents.⁵ Several LMWHs have been approved for clinical use and have begun to replace heparin as the clinical anticoagulant of choice.⁶ These LMWHs have a major advantage when

¹Departments of Chemistry and Chemical Biology, Chemical and Biological Engineering, and Biology, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York; ²Department of Biochemistry and Molecular Biology, Oklahoma Center for Medical Glycobiology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; ³Division of Medicinal Chemistry and Natural Products, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

Address for correspondence and reprint requests: Robert J. Linhardt, Ph.D., Departments of Chemistry and Chemical Biology, Chemical and Biological Engineering, and Biology, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, 110 8th Street, Troy, NY 12180 (e-mail: linhardt@rpi.edu).

New Anticoagulants; Guest Editors, Job Harensberg, M.D., and BenitoCasas, Ph.D.


Figure 1 Primary structure and structural variability of a heparin chain with high affinity for antithrombin III (AT). GlcN, glucosamine; IdoA, iduronic acid; GlcA, glucuronic acid; S, sulfite; Ac, acetyl.

compared with heparin: they are subcutaneously bioavailable, resulting in their improved pharmacodynamics and allowing their application on an outpatient basis.\textsuperscript{5,6}

CURRENT LIMITATIONS FOR DEVELOPMENT OF THE NEXT GENERATION OF AGENTS

LMWHs still retain several problems also associated with heparin, despite the major improvements associated with their introduction. Both heparin and LMWHs are prepared from animal sources, raising concerns about viral and prion-based contamination,\textsuperscript{2,6} and limiting the amount of drug that can be produced easily.\textsuperscript{2} Heparin and LMWHs are also polydisperse, polycomponent, polypharmacologic agents, making the analysis and control of these drugs difficult.\textsuperscript{1,5,6} Finally, both heparin and LMWHs can cause severe side effects such as hemorrhage and heparin-induced thrombocytopenia (HIT).\textsuperscript{7}

Recognizing the limitation of these polycomponent drugs, a homogenous synthetic pentasaccharide, fondaparinux, was developed and introduced (Arixtra, GSK, Brentford, UK) that binds AT specifically and inhibits the serine protease inhibitor FXa.\textsuperscript{8} Fondaparinux, which has been approved for clinical use, has not been a commercial success. The chemical synthesis of fondaparinux is both complicated and costly,\textsuperscript{9} and the high cost of fondaparinux has not been justified by pharmacologic improvements compared with heparin and LMWHs.\textsuperscript{8,10} Furthermore, fondaparinux still retains the major side effect of hemorrhage and carries a slight risk of HIT.\textsuperscript{10} Other synthetic heparin analogs under development are also unlikely to be successful without major improvements in the field of synthetic carbohydrate chemistry.\textsuperscript{11}

The need for improved heparin-based anticoagulants still remains. An ideal agent would (1) not be derived from animal sources; (2) be relatively inexpensive to prepare in amounts suitable for the growing market in anticoagulant drugs; (3) be a single component or a structurally defined multicomponent agent; (4) exhibit excellent bioavailability and pharmacodynamic/pharmacokinetic profiles; and (5) show reduced side effects, particularly with regard to hemorrhage and HIT. This article discusses recently developed enabling technologies that might pave the way for the development of new heparin-based anticoagulants beyond the LMWHs. These enabling technologies include major advances in (1) our understanding of GAG biosynthesis; (2) chemical carbohydrate synthesis; (3) enzyme-based GAG synthesis; (4) micro- and nano-display of GAGs; (5) online GAG analysis; and (6) microarray and microfluidic platforms.

The next generation of anticoagulants should show nearly ideal chemical, biochemical, and pharmacological properties to ensure their development as pharmaceuticals within the next few decades. Finally, a platform useful for preparing such carbohydrate-based anticoagulant agents would represent a form of artificial Golgi, and as such, would provide an improved understanding of the biosynthesis of heparin and the closely related GAG, heparan sulfate (HS), within the cell as well as the underlying controls of GAG biosynthesis.

GAG BIOSYNTHESIS

Lindahl et al\textsuperscript{12} have studied heparin/HS biosynthesis extensively. Heparin and HS are structurally similar in that all of the disaccharide units found in heparin are also observed in HS and all of the disaccharide units found in HS are also observed in the heparin.\textsuperscript{13,14} Moreover, several extended sequences, such as high/low-sulfated domains and the AT-binding site (Fig. 1), can be found in both heparin and HS.\textsuperscript{14} Heparin and HS differ primarily in the amount of each disaccharide that they contain.\textsuperscript{15} For example, in HS, d-glucuronic acid is the major uronic acid, more than half of the glucosamine residues are N-acetylated, and there is an average of one sulfated group per disaccharide. In contrast, heparin has higher concentrations of a-L-iduronic acid and N-sulfot-\textbeta-d-glucosamine residues, and an average of two to three sulfated groups per disaccharide.\textsuperscript{12} Heparin and HS contain at least 10 different sugar units,\textsuperscript{13,14} complicating efforts to sequence these polysaccharides.\textsuperscript{16–20}

Similar biosynthetic pathways process heparin and HS.\textsuperscript{12,21–23} First, the core protein is synthesized and then a tetrasaccharide linker is attached to specific serine residues.\textsuperscript{24,25} From this linkage, a repeating 1→4
glycosidically linked copolymer of β-d-glucuronic acid and N-acetyl-β-d-glucosamine, called heparosan, is synthesized through the stepwise addition of uridine diphosphate (UDP)-activated sugars.\textsuperscript{12} Heparosan can also be biosynthesized by bacteria, including \textit{Escherichia coli} and \textit{Pasteurella multocida}.\textsuperscript{26,27} During its synthesis in animal cells, the heparosan linear homocopolymer is modified sequentially through the action of N-desacyl-\textit{N}-sulfotransferase, C-5 epimerase, and 2-, 6-, and 3-O-sulfotransferases (OSTs). Complete or nearly complete modification of this nascent GAG chain results in a highly \textit{N}- and \textit{O}-sulfate-modified, α-L-iduronic acid-rich GAG called heparin.\textsuperscript{3} Partial modification of the same chain results in an \textit{N}-acetyl-β-d-glucosamine, β-d-glucuronic acid-rich GAG called HHS.\textsuperscript{28,29} All of the enzymes involved in the biosynthesis of heparin and HHS have been cloned and expressed. Many of these biosynthetic enzymes (i.e., 3-OST, 6-OST) have multiple isoforms\textsuperscript{30-33} that show temporal- and tissue-specific expression.\textsuperscript{32,34} Despite these major advances in our understanding of GAG biosynthesis, it is still unclear how biosynthesis is controlled (i.e., extent, type of chain modification, and domain placement).\textsuperscript{21,29}

Heparin is biosynthesized as a proteoglycan called serglycin,\textsuperscript{24} and pharmaceutical heparin generally is obtained from animal tissues rich in serglycin-containing mast cells,\textsuperscript{35} including porcine intestine or bovine lung. Pharmaceutical heparin, commercially prepared in metric ton quantities, ranges in molecular weight from 5000 to 40,000, with an average molecular weight of 12,000.\textsuperscript{12}

### CHEMICAL CARBOHYDRATE SYNTHESIS

**Limitations in the Chemical Synthesis of Heparin**

Despite recent advances,\textsuperscript{11,36} the total chemical synthesis of heparin, heparin oligosaccharides, and derivatives using current state-of-the-art techniques, has serious limitations. The multiple steps required by Sinay\textsuperscript{9} and van Boeckel\textsuperscript{37} to chemically synthesize an intricately substituted heparin oligosaccharide, although it displays elegant chemistry,\textsuperscript{9,36,37} results in a product that simply costs too much. Indeed, much synthetic work has focused on simplifying the target structure (i.e., replacing 2-amino-2-deoxy-d-glucose with d-glucose to prepare active analogs)\textsuperscript{11,37-39} rather than optimizing the synthesis of the natural product. Although recent advances in the chemical synthesis of heparin oligosaccharides by Thollas et al.,\textsuperscript{40} Jacquinet et al.,\textsuperscript{41} Prabhoo et al.,\textsuperscript{42} Lohman et al.,\textsuperscript{43} Orgueiras,\textsuperscript{44} and others\textsuperscript{45-47} have decreased the number of synthetic steps, increased stereoregularity, and enhanced yields, each new target still represents a major research commitment. Despite problems inherent to the chemical synthesis of heparin oligosaccharides, the synthetic AT-binding pentasaccharide, fondaparinux, was introduced as a clinical anticoagulant in both the United States and Europe.\textsuperscript{4} Although the approval of fondaparinux represents a drug development success, the commercial outlook for this expensive product is not bright.

![Figure 2](image_url)

\textbf{Figure 2} Natural and unnatural uridine diphosphate donors.

\[
\begin{align*}
R &= \text{H or TFESO}_2 \\
R' &= \text{HCOCH}_3, \text{H, HCOCF}_3, \text{N}_2
\end{align*}
\]
Prospects for Synthetic UDP Sugars in Enzymatic Synthesis of GAGs

UDP sugar donors, UDP-\(N\)-acetylglucosamine and UDP-glucuronic acid, are routinely used in the laboratory for studying heparin/HS biosynthesis.\(^{33}\) Recently, unnatural UDP monosaccharide donors have been synthesized and used successfully to study the structure–activity relationship of an antibiotic glycosides, such as vancomycin.\(^{48}\) Other unnatural UDP monosaccharide donors, such as UDP-iduronic acid, UDP-2-azidoglucose, UDP-\(N\)-trifluoroacetylglucosamine, and donors containing trifluoroethyl (TFE)−protected sulfo groups,\(^{49}\) are currently under intensive investigation (Fig. 2). Although it is unclear if synthases/glycosyltransferases will accept all of these unnatural donors in place of their natural UDP-\(N\)-acetylglucosamine and UDP-glucuronic acid substrates, preliminary studies demonstrate that UDP-\(N\)-trifluoroacetylglucosamine is readily accepted in place of UDP-\(N\)-acetylglucosamine. Modeling of donors with neutral TFE-protected sulfo groups suggests that they can be accommodated by synthases/glycosyltransferases. These unnatural UDP donors can be synthesized chemically, by glycosylation of activated sugar with UDP, or enzymatically from the 1-phosphosugar. Given that these donors contain only a single glycosidic linkage, their synthesis in multiple-gram amounts is relatively uncomplicated, suggesting the potential application of these unnatural UDP donors in the preparation of chemo-enzymatically synthesized heparins.

ENZYME-BASED GAG SYNTHESIS

Synthase-Catalyzed Preparation of Unsulfated GAGs

Polysaccharide synthases are the glycosyltransferase enzymes that catalyze the polymerization of activated sugars to form GAGs (Table 1).\(^{30-32}\) Synthase activity typically is associated with either the plasma membrane (in prokaryotes) or the Golgi apparatus membranes (in eukaryotes). Some species of pathogenic bacteria take advantage of the endogenous role of GAGs in cell-cell interaction and cellular communication in their animal hosts. The bacteria form surface coatings (polysaccharide capsules) that comprise GAGs identical or chemically similar to host molecules.\(^{53}\) Certain pathogenic strains of E. coli and P. multocida make capsules composed of polymers very similar to HS. These GAG-like polymers are not immunogenic and protect the bacteria from host defenses. Indeed, these microbes use their GAGs as molecular camouflage.

Membrane-bound synthase/glycosyltransferase proteins are difficult to handle, thus, few enzymes have been identified through biochemical purification. A larger number of synthases/glycosyltransferases have been sequenced at the nucleotide level, cloned, and expressed. Despite these advances, molecular details on their three-dimensional native structures, active sites, and catalytic mechanisms are very limited. The exploration of these enzymes for GAG synthesis is just beginning in our laboratories,\(^{54}\) but a few of these catalysts have been harnessed as practical chemoenzymatic tools.

<table>
<thead>
<tr>
<th>GAG</th>
<th>Species</th>
<th>GAG-Transferases</th>
<th>UDP Donors</th>
<th>Acceptors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyaluronan</td>
<td>Vertebrae</td>
<td>Class I HAS 1,2,3</td>
<td>GlcNAc, GlcA</td>
<td>(GlcNAc-GlcA(<em>{n&gt;1}), GlcA-GlcNAc(</em>{n&gt;2}))</td>
</tr>
<tr>
<td>Streptococcus</td>
<td>Chlorella</td>
<td>Class I sPHAS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Virus</td>
<td>Pasteurella</td>
<td>Class II pmHAS</td>
<td>GlcNAc, GlcA</td>
<td></td>
</tr>
<tr>
<td>Chondroitin</td>
<td>Vertebrates</td>
<td>ChSy</td>
<td>GalNAc, GlcA</td>
<td>(GalNAc-GlcA(<em>{n&gt;1}), GlcA-GalNAc(</em>{n&gt;2}))</td>
</tr>
<tr>
<td>Pasteurella</td>
<td>pmCS, KfoC</td>
<td>GalNAc, GlcA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyaluronan/chondroitin</td>
<td>Racombinant chimeric</td>
<td>pmHAS/pmCS</td>
<td>GalNAc</td>
<td>(HexGlcNAc-GlcA(_{n&gt;1}), GlcN, GlcNAc, GlcA)</td>
</tr>
<tr>
<td>Heparan</td>
<td>Vertebrates</td>
<td>EXT 1,2</td>
<td>GlcNAc, GlcA</td>
<td>(GlcNAc-HexA(<em>{n&gt;1}), GlcA-GlcNAc(</em>{n&gt;2}))</td>
</tr>
<tr>
<td>Heparosan</td>
<td>Pasteurella</td>
<td>pmHS 1,2</td>
<td>GlcNAc, GlcA</td>
<td>(GlcNAc-GlcA(<em>{n&gt;1}), GlcA-GlcNAc(</em>{n&gt;2}))</td>
</tr>
<tr>
<td>Escherichia</td>
<td>Kfa – KfC (2 proteins needed)</td>
<td>GlcNAc, GlcA</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

UDP, uridine diphosphate; HAS, hyaluronan synthase; GlcNAc, \(N\)-acetylglucosamine; GlcA, glucuronic acid; ChSy, chondroitin synthase; CS, chondroitin sulfate; HS, heparan sulfate.
Enzyme Catalyzed Synthesis of Sulfated GAGs
The HS biosynthetic enzymes have been expressed in E. coli as truncated (no transmembrane domain) fusion proteins using a bacterial cell line that coexpresses a chaperone. Chaperones help recombinant proteins fold correctly to obtain functional proteins. These recombinant proteins have comparable specific enzymatic activities and substrate specificity of those expressed in mammalian and insect cells.

Enzymatically Designing the Functions of Heparin/HS
An enzymatic approach has been developed to synthesize heparin from completely desulfonated N-sulfonated heparin. Although this clearly is not a viable commercial approach, it serves to demonstrate that much of the technology is in hand to synthesize heparin chemically. Only three enzymatic steps are required for the synthesis of heparin with anticoagulant activity from desulfonated N-sulfonated heparin (Fig. 3). The

**Figure 3** Schematic synthesis of sulfonated polysaccharides and 3'-phosphoadenosine-5'-phosphosulfate (PAPS) regeneration system. (A) The stepwise enzymatic synthesis of sulfonated polysaccharides using heparan sulfate (HS) sulfotransferases. The description of intermediate polysaccharides is shown in the text. Compounds 4a and 4b were prepared by inverting the order of sulfonation steps. 4a was prepared by incubating compound 1 with 2-O-sulfotransferase (2-OST) followed by 6-OST, whereas 4b was prepared by incubating compound 1 with 6-OST followed by 2-OST. (B) The reaction catalyzed by arylsulfotransferase IV to generate PAPS.
Table 2 Summary of the Disaccharide Compositions of the Synthetic Poly saccharides*

<table>
<thead>
<tr>
<th>Compound</th>
<th>△UA-GlcNac (nmole) (%)</th>
<th>△UA-GlcNS (nmole) (%)</th>
<th>△UA2S-GlcNS (nmole) (%)</th>
<th>△UA-GlcNS6S (nmole) (%)</th>
<th>△UA2S-GlcNS6S (nmole) (%)</th>
<th>Total Recovery (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>12.5 (16.1%)</td>
<td>50.9 (64.4%)</td>
<td>6.3 (8.1%)</td>
<td>6.3 (8.1%)</td>
<td>2.5 (3.2%)</td>
<td>54.0</td>
</tr>
<tr>
<td>2</td>
<td>12.5 (16.6%)</td>
<td>27.5 (36.6%)</td>
<td>30.0 (40.0%)</td>
<td>2.5 (3.5%)</td>
<td>2.5 (3.5%)</td>
<td>49.2</td>
</tr>
<tr>
<td>3</td>
<td>10.0 (14.0%)</td>
<td>27.5 (38.5%)</td>
<td>5.0 (7.0%)</td>
<td>25.0 (35.0%)</td>
<td>3.5 (5.3%)</td>
<td>51.0</td>
</tr>
<tr>
<td>4a</td>
<td>12.5 (18.8%)</td>
<td>17.5 (26.2%)</td>
<td>7.5 (11.2%)</td>
<td>10.0 (15.0%)</td>
<td>20.0 (30.0%)</td>
<td>50.0</td>
</tr>
<tr>
<td>4b</td>
<td>17.5 (27.1%)</td>
<td>15.0 (23.6%)</td>
<td>8.0 (6.6%)</td>
<td>15.0 (18.6%)</td>
<td>25.0 (31.0%)</td>
<td>48.0</td>
</tr>
</tbody>
</table>

*Each synthesized polysaccharide 100 μg was digested with a mixture of heparinases. The resultant disaccharides were purified by HPLC (Bio-Gel P-2 column), and resolved by reversed-phase ion-pair partition high-performance liquid chromatography.

Table 3 Anti-Factor Xa and Antithrombin III (AT) Activities of the Synthesized Poly saccharide Intermediates

<table>
<thead>
<tr>
<th>Sample</th>
<th>Factor Xa Inhibition* (IC50, ng/mL)</th>
<th>Thrombin Inhibition* (IC50, ng/mL)</th>
<th>Binding to AT (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heparin</td>
<td>20</td>
<td>10</td>
<td>ND</td>
</tr>
<tr>
<td>HS5</td>
<td>&gt;5000</td>
<td>&gt;3000</td>
<td>ND</td>
</tr>
<tr>
<td>Fondaparinux</td>
<td>58</td>
<td>&gt;3000</td>
<td>5%</td>
</tr>
<tr>
<td>4</td>
<td>&gt;2000</td>
<td>&gt;3000</td>
<td>ND</td>
</tr>
<tr>
<td>7</td>
<td>126</td>
<td>96</td>
<td>31%</td>
</tr>
<tr>
<td>5</td>
<td>40</td>
<td>32</td>
<td>38%</td>
</tr>
</tbody>
</table>

*The procedures for measuring the activities of Factor Xa and thrombin are described elsewhere.

The current study demonstrates two major advantages that may permit the large-scale synthesis of heparin. First, large amounts of all the required m-OST enzymes have been expressed successfully in E. coli (as described) and immobilized on solid supports packed into bioreactors. Second, a 3'-phosphoadenosine-5'-phosphosulfate (PAPS) regeneration system, developed by Burkard et al., has been coupled to the enzymatic synthesis reactions. This PAPS regeneration system alone reduces the cost of the synthesis by more than 1000-fold, making the large-scale enzymatic synthesis possible.

PAP (3',5'-phosphoadenosine) is formed when the sulfo group is transferred to an acceptor. A PAPS regeneration system converts PAP to PAPS through the action of recombinant arylsulfotransferase-IV, which catalyzes the transfer of sulfo group from p-nitrophenyl sulfate (PNPS) to PAP (Fig. 3B). This system is essential for the large-scale synthesis for the following reasons. First, PAP inhibits the HS OSTs with concentration that inhibits 50% values of ~100 μM, making milligram-scale synthesis difficult without continuously removing PAP. Second, a PAPS regeneration system permits the PNPS as the sulfo donor and catalytic amounts of PAP, consequently reducing the cost of synthesis.

The PAPS regeneration system performs very well with immobilized 2-OST, 6-OST, and 3-OST-1. Under the standard conditions, 2-OST, 6-OST, and 3-OST-1 afforded 98%, 97%, and 98% complete modification, respectively. The incorporation of 2-O-sulfo and 6-O-sulfo groups can be confirmed using disaccharide analysis of the structures of the newly synthesized poly saccharide products 2, 3 and 4a and 4b. Approximately 1.5 mg of AT-binding HS (5, see Fig. 1) was synthesized from 10 mg of completely desulfated N-sulfated (CDSNS) heparin (I) using this approach.

Synthesized polysaccharide intermediates were digested with a mixture of heparinases, and the resulting disaccharides were analyzed using reversed-phase ion-pair partition high-performance liquid chromatography. Analysis of 1 showed a disaccharide component of the structure of △UA5-GlcNS (△UA is 4-deoxy-α-L-threo-

hex-4-enopyranosyluronic acid, is pyranoside), residual unsulfated disaccharide, △UA5-GlcNpAc, and small amounts of sulfated disaccharides due to incomplete chemical desulfonation (Table 2). The modification by 2-OST elevated the level of △UA2S-GlcNpS by ~5-fold (Table 3), confirming the structure of 2. Analysis of 3 afforded a 7-fold increase in the level of the disaccharide △UA6-GlcNS6S compared with 1, consistent with 6-OST catalyzed modification (Table 2). The level of trisulfodisaccharide, △UA62-GlcNS6S in 4a and 4b, was increased by ~10-fold compared with that of 1 (Table 2). These results clearly establish that the expected enzymatic modifications took place at each step. It is interesting to note that 6-O-sulfation occurs at N-sulfoglucosamine, consistent with the substrate specificity of 6-OST in vitro. The 2-O-sulfation occurs predominantly at the uronic acid with an N-sulfoglucosamine residue at the reducing end. Interestingly, substantial amounts of △UA5-GlcNS5 remain in 4a and 4b. This observation is not unexpected given that the HS from various tissues also...
contain ΔUA₁₄-Glc₂NS disaccharide unit, suggesting that the structures of 4a and 4b are similar to HS from natural sources. H-nuclear magnetic resonance analyses on these polysaccharides were found to be consistent with the disaccharide analysis.35

Characterization of the affinities of AT to heparin and enzymatically modified heparin derivatives (1–5) relied on surface plasmon resonance (SPR).35 A two-state reaction model was applied to the SPR study. None of the derivatives, with the exception of the 2,6,3-O-sulfo polysaccharide (5) and heparin, had high affinity to AT. The binding constant (K_D) for the binding of 2,6,3-O-sulfo polysaccharide 5 to AT was 170 nM, comparable to that of pharmaceutical heparin (75 nM).

Because it is known that the introduction of the 3-O-sulfo group by 3-OST-1 is essential for the synthesis of anticoagulant heparin, the FXa and thrombin activities of polysaccharides 5, 6, and 7 were evaluated (Table 3). As expected, heparin was a potent activator for AT-mediated inhibition of FXa and thrombin, whereas fondaparinux specifically activates the AT-mediated inhibition of FXa.47 Polysaccharide 5 has very similar potency to heparin, inhibiting the activities of both FXa and thrombin, suggesting that an enzyme-based approach is indeed capable of synthesizing an anticoagulant heparin polysaccharide. It has been reported that the presence of 2-O-sulfo groups is not essential for HS binding to AT and its resulting anticoagulant activity.63 Indeed, polysaccharide intermediate 7 lacks 2-O-sulfo groups but still exhibits anticoagulant activity, consistent with a previous report.63 In contrast, 6 lacks 6-O-sulfo groups, and thus has no anticoagulant activity, given that 6-O-sulfo groups are critical in AT binding.64 The AT binding affinities of the synthesized polysaccharides were also determined (Table 3), demonstrating that the anticoagulant activities of the compounds correlated to their binding affinity to AT. Taken together, these results demonstrate that the structure and anticoagulant activities of the enzymatically synthesized polysaccharide 5 were consistent with the known structure and activity of heparin (Fig. 1).

**ON-LINE GAG ANALYSIS**

Recent advances in mass spectrometry suggest that it is now possible to analyze intact heparin/HS chains. Electrospray ionization mass spectrometry (MS), useful as an on-line analytical tool, has been used effectively to analyze heparin oligosaccharides of molecular mass as high as 7 kD.65 MS-MS methods allow for the positioning of sulfo groups within the GAG chain.66 Electron capture dissociation–MS can be used to differentiate iduronic acid from glucuronic acid residues.67 These advances in MS analysis should be applicable to the real time analysis of polysaccharide chains synthesized in microfluidic devices. In addition, the recent use of matrix-assisted laser desorption ionization (MALDI)-MS for the direct analysis of uncomplexed sulfated oligosaccharides on a target surface68,69 suggests that it might be possible to use MALDI-MS for the analysis of heparin/HS on the surface of a microarray synthesizer (described in “Microarrays”).

**MICRO- AND NANO-DISPLAY OF GAGS**

Solid-phase synthesis of biopolymers offers a number of advantages as it does in peptide synthesis, maximizing yields and minimizing separation problems.70 Although heparin and heparin oligosaccharides have been coupled to macroscopic supports such as affinity resins71 for several years, such chemistry has only recently been applied to nano-based carriers.72,73 The size of such nanocarriers resembles the dimensions of the core protein of heparin/HS proteoglycans (Fig. 4). These nanoglycoconjugates are soluble,25 in buffer solutions, allowing their movement in microfluidic systems. Furthermore, nanocarriers such as gold74 and quantum dots exhibit optical properties that facilitate their detection and analysis. These rapidly developing technologies suggest the use of nanocarriers as solid supports for the enzyme-based synthesis of heparin in microfluidic reactors. GAGs can be synthesized on a solid phase (plastic, glass, metal, etc.) using enzyme catalysts.75

**MICROARRAY AND MICROFLUIDIC PLATFORMS**

Microarrays

Microarrays have been used for the screening of protein binding to heparin and heparin oligosaccharides.76,77

---

**Figure 4**  A schematic of a heparin glycosaminoglycan chain immobilized to a carbon nanotube.
The successful enzymatic modification of heparosan linked to a surface suggests that it might also be possible to synthesize libraries of heparins in a microarray format. A microarray of up to 5000 addressable spots can be printed on a glass microscope slide. Each spot can be designed to contain a polysaccharide for modification by C-5 epimerase and OSTs or an oligosaccharide for extension with glycosyltransferase and subsequent enzymatic modification. Such a large microarray could then be screened and be probed with heparin-binding proteins. One might envision using microarrays to identify an enzymatically synthesized heparin able to bind AT and inhibit thrombin and FXa without binding platelet factor 4, thus preventing HIT. Glycosylation of each microarray spot would rely on MALDI-MS, and once characterized, a chain with desirable biochemical and pharmacological properties could be synthesized in large scale for exploitation as a

**Figure 5** Solid-phase synthesis of heparin from N-sulfoheparosan. Epi, ???; OST, O-sulfotransferase; AT, antithrombin III.
novel pharmaceutical agent. Such devices might even be useful for introducing designer heparins, fine-tuned to an individual patient. Such a pharmacogenetic approach requires a high-throughput platform to be practicable.

**FUTURE PROSPECTS**

**Glycosylation Using Continuous-Flow Microfluidics**

In early studies, Hernaiz et al. demonstrated that 3-OST-1 could be used to convert inactive HS (incapable of binding AT) into active (AT binding) HS in a microfluidic system. On the basis of this initial success, four enzymes involved in heparin/HS biosynthesis were cloned and expressed in *E. coli*. These enzymes were then used in solution-phase chemistry to regenerate an active AT-binding site within a chemically modified heparin polysaccharide. This approach was next extended to modify heparan, a bacterial capsular polysaccharide purified from *E. coli* KS, having the structure → 4)-α-D-N-acetylglucosamine (1→ 4)-β-D-glucuronic acid (1→. This polysaccharide was chemically de-N-acetylated and N-sulfonated to afford N-sulfoheparan, having the structure → 4)-α-D-N-sulfoglucosamine (1→ 4)-β-D-glucuronic acid (1→. N-sulfoheparan was immobilized onto a microfluid, flow cell-based, SPR sensor chip (Fig. 3). An interacting AT analyte was flowed over the chip and AT-polysaccharide (ligand) binding was measured using SPR. As expected, AT failed to bind to N-sulfoheparan because this ligand lacks the requisite structure comprising the AT-binding site (Fig. 5). Biosynthetic enzymes and appropriate cofactors, which had been applied previously to solution-phase synthesis, were used to modify the N-sulfoheparan ligand immobilized to the surface of the microfluidic biosensor chip. When the correct enzymes and cofactors were applied in the correct sequence, an AT-binding site was introduced into the immobilized ligand. After this modification, the AT analyte bound to the ligand on the biosensor chip with the expected affinity, confirming that the biosynthetic enzymes were capable of acting in this microfluidic reactor. Unfortunately, because there was insufficient control within the reactor, only a small number of the resulting chains contained the desired AT binding site. Furthermore, the placement of this site at a precise position within the chain could not be accomplished.

Related preliminary experiments have also demonstrated that heparin polysaccharides can be immobilized covalently onto nanoparticle carriers and that enzymes are capable of acting on the nanoparticle-immobilized polysaccharide. Furthermore, the heparin/HS biosynthetic enzymes have been expressed as fusion proteins, immobilized to solid supports through their fusion protein domains, and demonstrate high stability and retention of activity.
including controlled access of enzymes to protein-core-containing oligosaccharide acceptors, assembly of multienzyme complexes, and access to cofactors and substrates.

Research currently is underway to construct an artificial Golgi using microfluids for the controlled synthesis of heparin on nanosupports and using on-line product analysis (Fig. 7). Such a system will require additional development and integration of all of the enabling technologies discussed in this article. The resulting device will serve as both a test device for the understanding of Golgi function and regulation as well as a reactor for the generation of structurally defined heparins with discrete biological activities.

REFERENCES

1. Linhardt RJ. Heparin: an important drug enters its seventh decade. Chem Ind 1991;2:45-50
2. Linhardt RJ, Gunay NS. Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost 1999;25:3-14


41. Jaquenot J-C. An expedient preparation of various sulfosulfates of the disaccharide β-D-Galp-(1→3)-D-Galp, a partial structure of the region of proteoglycans, as their 4-methoxyphenyl β-D-glycosides. Carbohydr Res 2004;339:349–359


74. Psaltis D, Quake SR, Yang C. Developing optofluidic technology through the fusion of microfluidics and optics. Nature 2006;442:381–386.


